Dr. Zhou is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4921 Parkview Pl
Saint Louis, MO 63110Phone+1 314-362-7216Fax+1 314-362-8813
Summary
- Dr. Amy Zhou is an oncologist based in Saint Louis, MO, who specializes in Hematology and Medical Oncology. She completed her Internal Medicine Residency at Emory University School of Medicine and then pursued her Hematology and Medical Oncology fellowship at Washington University in St. Louis. Her research focus on MPNs is exemplified by her numerous notable publications, some of which have been cited multiple times by other healthcare professionals. Dr. Zhou's active roles in clinical trials emphasize her dedication to finding improved treatment methods, particularly for patients with MPNs.
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2013 - 2016
Emory University School of MedicineResidency, Internal Medicine, 2009 - 2012
Wayne State University School of MedicineClass of 2009
Certifications & Licensure
MO State Medical License 2016 - 2026
PA State Medical License 2012 - 2014- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia Start of enrollment: 2021 May 03
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 1 citationsA phase I trial of pevonedistat in combination with ruxolitinib for the treatment of myelofibrosis.Tim Kong, Nicole Gaudin, Karyn Gordon, Maggie J Cox, Amy W Zhou
Therapeutic Advances in Hematology. 2024-01-01 - 5 citationsHematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor.Zachary D Crees, Michael P Rettig, Asad Bashey, Steven M Devine, Samantha Jaglowski
Blood Advances. 2023-09-26 - 12 citationsHepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib.Amy Zhou, Tim Kong, Jared S Fowles, Chun-Ling Jung, Maggie J Allen
British Journal of Haematology. 2022-05-01
Abstracts/Posters
- Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion...Amy Zhou, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Altered Dynamics of Monocyte Subpopulations and Pro-Inflammatory Signaling Pathways in Polycythemia Vera Revealed By Mass CytometryAmy Zhou, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
